Attached files
file | filename |
---|---|
8-K - FORM 8-K - BAXTER INTERNATIONAL INC | c65492e8vk.htm |
Baxter International Inc. One Baxter Parkway Deerfield, Ill., 60015 |
FOR IMMEDIATE RELEASE
Media Contact:
Deborah Spak, (847) 948-2349
Deborah Spak, (847) 948-2349
Investor Contacts:
Mary Kay Ladone, (847) 948-3371
Clare Trachtman, (847) 948-3085
Mary Kay Ladone, (847) 948-3371
Clare Trachtman, (847) 948-3085
BAXTERS SECOND QUARTER FINANCIAL RESULTS EXCEED GUIDANCE;
COMPANY RAISES FULL-YEAR FINANCIAL OUTLOOK
COMPANY RAISES FULL-YEAR FINANCIAL OUTLOOK
Baxter Reports Double-Digit Growth in Q2 Sales and Earnings
DEERFIELD,
Ill., July 21, 2011 Baxter International Inc. (NYSE:BAX) today announced strong
financial results for the second quarter of 2011, and raised its financial outlook for full-year
2011.
Baxter reported net income of $615 million in the second quarter, an increase of 15 percent
compared to $535 million reported in the same period last year. Earnings per diluted share of
$1.07 advanced 19 percent from $0.90 per diluted share in the prior-year period, and exceeded the
companys previously issued earnings guidance of $1.01 to $1.03 per diluted share. This
performance reflects double-digit sales growth, operational leverage, favorable foreign exchange
and the benefit from the companys ongoing share repurchase program.
On an adjusted basis, excluding a special item in the second quarter of 2010, Baxters net
income and earnings per diluted share increased 10 percent
- more -
BAXTER REPORTS 2nd QUARTER FINANCIAL RESULTS Page 2
and 15 percent, respectively, from $557 million and $0.93 per diluted share recorded in the
prior-year period.
Worldwide sales totaled $3.5 billion and increased 11 percent compared to sales of $3.2
billion in the second quarter of 2010. Excluding the impact of foreign currency, worldwide sales
increased 6 percent. Sales within the United States grew 5 percent to $1.4 billion, while
international sales of $2.1 billion accelerated 15 percent (or 7 percent excluding the impact of
foreign currency).
BioScience revenues totaled $1.6 billion, representing a 14 percent increase from $1.4 billion
in the comparable prior-year period. Excluding the impact of foreign currency, BioScience sales
advanced 10 percent boosted by strong demand for GAMMAGARD LIQUID [Immune Globulin Intravenous
(Human)] (marketed as KIOVIG outside of the United States), certain specialty plasma-based
therapeutics, and vaccines.
Medical Products sales increased 8 percent to $2.0 billion from $1.8 billion reported last
year. Excluding the impact of foreign currency, Medical Products sales increased 3 percent. As
previously disclosed, the company completed the divestiture of its U.S. multi-source generic
injectables business to Hikma Pharmaceuticals PLC during the quarter. Excluding generic
injectables sales from both years, Medical Products revenues increased 10 percent (or 5 percent
excluding the impact of foreign currency), reflecting strong growth of anesthesia products,
nutritional therapies, infusion systems and other injectable drugs.
We remain encouraged with the continued improvement in our financial performance and progress
with the initiatives we have implemented to enhance our commercial, operational, and scientific
effectiveness, said Robert L.
- more -
BAXTER REPORTS 2nd QUARTER FINANCIAL RESULTS Page 3
Parkinson, Jr., chairman and chief executive officer. These initiatives, combined with
Baxters global presence, diversified portfolio, and focus on innovation, provide unique
opportunities for future growth in an evolving and challenging macro-environment.
Six-Month Results
For the first six months of 2011, Baxter reported net income of $1.2 billion or $2.05 per
diluted share, compared to net income of $472 million or $0.78 per diluted share in the same period
last year. On an adjusted basis, excluding special items in the first half of 2010, Baxters net
income for the six-month period increased 6 percent from $1.1 billion in the prior year, and
earnings per diluted share increased 10 percent from $1.86 per diluted share reported in the first
half of last year.
Baxters worldwide sales totaled $6.8 billion and increased 11 percent (or
9 percent excluding the impact of foreign currency) compared to sales of
$6.1 billion in the same period of 2010. Sales in 2010 included a revenue adjustment associated
with the COLLEAGUE infusion pump of $213 million. Excluding this revenue adjustment, Baxters
worldwide sales increased 8 percent over the prior six-month period (or 5 percent excluding the
impact of foreign currency).
During the first six months of this year, Baxter returned approximately
$1.5 billion to shareholders through both dividends and share repurchases. The company paid
dividends totaling $358 million and repurchased 21 million shares of Baxter common stock for $1.1
billion.
- more -
BAXTER REPORTS 2nd QUARTER FINANCIAL RESULTS Page 4
Recent Highlights
Baxter continued to enhance its portfolio and new product pipeline through investments in
research and development, augmented by new business development initiatives. Recent achievements
include the following:
| Acquisition of privately-held Prism Pharmaceuticals, Inc., a specialty pharmaceutical company, and the subsequent launch of NEXTERONE® (amiodarone HCl) Premixed Injection in the United States. This is the first and only ready-to-use premixed formulation of the antiarrhythmic agent amiodarone, which is immediately available for use and reduces the risk of medication errors associated with compounding. | ||
| Divestiture of the companys U.S. generic injectables business to Hikma Pharmaceuticals PLC. The sale of this business, which was completed in early May, allows Baxter to redirect resources toward its proprietary, enhanced packaging offerings and formulation technologies, consistent with the companys focus on product differentiation. | ||
| Submission of a Biological License Application to the U.S. Food and Drug Administration for HyQ, a subcutaneous immune globulin therapy facilitated by recombinant human hyaluronidase for use in patients with primary immunodeficiency. The company also announced top-line results of a phase III study of HyQ, which confirmed the interim results presented in late 2010. | ||
| Positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for extension of the therapeutic indications of KIOVIG (marketed as GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] in the United States) to include multifocal motor neuropathy (MMN), a chronic condition characterized by progressive limb weakness. Upon adoption by the European Commission, Baxter will receive marketing authorization in all European Union Member States representing the first centrally-licensed indication for an immunoglobulin preparation for MMN. | ||
| Publication of Phase II data in Circulation Research demonstrating that injections of a patients own CD34+ adult stem cells into targeted sites in the heart have therapeutic benefits for patients with chronic myocardial ischemia (CMI). Benefits included reduction in frequency of angina episodes and improved exercise tolerance. More than 850,000 patients in the United States experience refractory angina associated with CMI and have not responded to other therapeutic options. |
- more -
BAXTER REPORTS 2nd QUARTER FINANCIAL RESULTS Page 5
| Award of the Best in KLAS distinction for the SIGMA Spectrum Infusion System by an independent research firm in its annual customer satisfaction report 2011 Top 20 Best in KLAS Awards: Medical Equipment & Infrastructure. The SIGMA Spectrum Infusion System scored the highest in overall performance, reliability and delivery of technology, and builds upon previous recognition of the highest perception ratings for Cost/Value and Ease of Use in an initial KLAS report released in the first quarter of 2011. |
Outlook for Third Quarter and Full-Year 2011
Baxter also announced today its guidance for the third quarter of 2011 and raised its
financial outlook for the full year.
For full-year 2011, Baxter now expects earnings, before special items, of $4.27 to $4.32 per
diluted share versus previous guidance of $4.20 to $4.28 per diluted share. Baxter continues to
expect to achieve sales growth of
3 to 4 percent, excluding special items and the impact of foreign currency (or
5 to 6 percent including the benefit of foreign currency). In addition, the company expects to
generate cash flows from operations of approximately $2.8 billion.
For the third quarter of 2011, the company expects sales growth, excluding the impact of
foreign currency, of 3 to 4 percent (or 6 to 7 percent including the benefit of foreign currency)
and earnings per diluted share of $1.07 to $1.09, before any special items.
A webcast of Baxters second quarter conference call for investors can be accessed live from a
link on the companys website at www.baxter.com beginning at 7:30 a.m. CDT on July 21, 2011.
Please visit Baxters website for more information regarding this and future investor events and
webcasts.
Baxter International Inc., through its subsidiaries, develops, manufactures and markets
products that save and sustain the lives of people with hemophilia,
- more -
BAXTER REPORTS 2nd QUARTER FINANCIAL RESULTS Page 6
immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute
medical conditions. As a global, diversified healthcare company, Baxter applies a unique
combination of expertise in medical devices, pharmaceuticals and biotechnology to create products
that advance patient care worldwide.
This release includes forward-looking statements concerning the companys financial results,
outlook for 2011 and R&D pipeline. The statements are based on assumptions about many important
factors, including the following, which could cause actual results to differ materially from those
in the forward-looking statements: demand for and market acceptance risks for new and existing
products, such as ADVATE, and other technologies; future actions of regulatory bodies and other
governmental authorities, including with respect to the companys implementation of the COLLEAGUE
recall, that could delay, limit or suspend product development, manufacturing or sales or result in
sanctions; product quality or patient safety concerns leading to product recalls, withdrawals,
launch delays, litigation, or declining sales; Sigmas ability to build production capacity to meet
customer demand; future actions of governmental authorities and other third parties as U.S.
healthcare reform legislation and other austerity measures are implemented; additional legislation,
regulation and other governmental pressures, which may affect pricing, reimbursement and rebate
policies of government agencies and private payers or other elements of the companys business;
product development risks; inventory reductions or fluctuations in buying patterns by wholesalers
or distributors; the impact of geographic and product mix on the companys sales; the impact of
competitive products and pricing, including generic competition, drug reimportation and disruptive
technologies; the availability of acceptable raw materials and component supply; fluctuations in
supply and demand and the pricing of plasma-based therapies; the ability to enforce company
patents; patents of third parties preventing or restricting the companys manufacture, sale or use
of affected products or technology; any impact of the current economic conditions on Baxter and its
customers; foreign currency fluctuations and other risks identified in the companys most recent
filing on Form 10-K and other Securities and Exchange Commission filings, all of which are
available on the companys website. The company does not undertake to update its forward-looking
statements. Financial schedules are attached to this release and available on the companys
website.
# # #
BAXTER PAGE 7
BAXTER INTERNATIONAL INC.
Consolidated Statements of Income
Three Months Ended June 30, 2011 and 2010
(unaudited)
(in millions, except per share and percentage data)
Consolidated Statements of Income
Three Months Ended June 30, 2011 and 2010
(unaudited)
(in millions, except per share and percentage data)
Three Months Ended | ||||||||||||
June 30, | ||||||||||||
2011 | 2010 | Change | ||||||||||
NET SALES |
$ | 3,536 | $ | 3,194 | 11% | |||||||
COST OF SALES |
1,701 | 1,556 | 9% | |||||||||
GROSS MARGIN |
1,835 | 1,638 | 12% | |||||||||
% of Net Sales |
51.9% | 51.3% | 0.6 pts | |||||||||
MARKETING AND ADMINISTRATIVE EXPENSES |
765 | 721 | A | 6% | ||||||||
% of Net Sales |
21.6% | 22.6% | (1.0 pt) | |||||||||
RESEARCH AND DEVELOPMENT EXPENSES |
239 | 219 | 9% | |||||||||
% of Net Sales |
6.8% | 6.9% | (0.1 pt) | |||||||||
NET INTEREST EXPENSE |
15 | 25 | (40%) | |||||||||
OTHER EXPENSE, NET |
13 | 3 | N/M | |||||||||
PRE-TAX INCOME |
803 | 670 | 20% | |||||||||
INCOME TAX EXPENSE |
174 | 133 | 31% | |||||||||
% of Pre-Tax Income |
21.7% | 19.9% | 1.8 pts | |||||||||
NET INCOME |
629 | 537 | 17% | |||||||||
LESS: NONCONTROLLING INTERESTS |
14 | 2 | N/M | |||||||||
NET INCOME ATTRIBUTABLE TO BAXTER |
$ | 615 | $ | 535 | 15% | |||||||
BASIC EPS |
$ | 1.08 | $ | 0.90 | 20% | |||||||
DILUTED EPS |
$ | 1.07 | $ | 0.90 | 19% | |||||||
WEIGHTED-AVERAGE
NUMBER OF COMMON SHARES OUTSTANDING |
||||||||||||
Basic |
570 | 593 | ||||||||||
Diluted |
575 | 596 | ||||||||||
ADJUSTED PRE-TAX INCOME (excluding specified item) |
$ | 803 | $ | 698 | B | 15% | ||||||
ADJUSTED NET INCOME ATTRIBUTABLE TO BAXTER (excluding specified item) |
$ | 615 | $ | 557 | B | 10% | ||||||
ADJUSTED DILUTED EPS (excluding specified item) |
$ | 1.07 | $ | 0.93 | B | 15% |
A | Marketing and administrative expenses in 2010 included a charge of $28 million ($22 million, or $0.03 per diluted share, on an after-tax basis) to write down accounts receivable in Greece, principally as a result of the anticipated settlement of certain accounts receivable with the Greek government. | |
B | Refer to page 8 for a description of the adjustment and a reconciliation to generally accepted accounting principles (GAAP) measures. |
BAXTER PAGE 8
BAXTER INTERNATIONAL INC.
Note to Consolidated Statements of Income
Three Months Ended June 30, 2011 and 2010
Description of Adjustment and Reconciliation of GAAP to Non-GAAP Measures
(unaudited)
(in millions, except per share and percentage data)
Note to Consolidated Statements of Income
Three Months Ended June 30, 2011 and 2010
Description of Adjustment and Reconciliation of GAAP to Non-GAAP Measures
(unaudited)
(in millions, except per share and percentage data)
The companys GAAP results for the three months ended June 30, 2010 included a specified item
which impacted the GAAP results as follows:
Three Months Ended June 30, | ||||||||||||||||||||
2011 | 2010 | |||||||||||||||||||
Greece | Excluding | |||||||||||||||||||
receivable | specified | |||||||||||||||||||
GAAP | 1 | GAAP | charge | 2 | item | Change | 3 | |||||||||||||
NET SALES |
$ | 3,536 | $ | 3,194 | $ | | $ | 3,194 | 11% | |||||||||||
COST OF SALES |
1,701 | 1,556 | | 1,556 | 9% | |||||||||||||||
GROSS MARGIN |
1,835 | 1,638 | | 1,638 | 12% | |||||||||||||||
% of Net Sales |
51.9% | 51.3% | 51.3% | 0.6 pts | ||||||||||||||||
MARKETING
AND ADMINISTRATIVE EXPENSES |
765 | 721 | (28 | ) | 693 | 10% | ||||||||||||||
% of Net Sales |
21.6% | 22.6% | 21.7% | (0.1 pt) | ||||||||||||||||
RESEARCH AND DEVELOPMENT EXPENSES |
239 | 219 | | 219 | 9% | |||||||||||||||
% of Net Sales |
6.8% | 6.9% | 6.9% | (0.1 pt) | ||||||||||||||||
NET INTEREST EXPENSE |
15 | 25 | | 25 | (40%) | |||||||||||||||
OTHER EXPENSE, NET |
13 | 3 | | 3 | N/M | |||||||||||||||
PRE-TAX INCOME |
803 | 670 | 28 | 698 | 15% | |||||||||||||||
INCOME TAX EXPENSE |
174 | 133 | 6 | 139 | 25% | |||||||||||||||
% of Pre-Tax Income |
21.7% | 19.9% | 19.9% | 1.8 pts | ||||||||||||||||
NET INCOME |
629 | 537 | 22 | 559 | 13% | |||||||||||||||
LESS: NONCONTROLLING INTERESTS |
14 | 2 | | 2 | N/M | |||||||||||||||
NET INCOME ATTRIBUTABLE TO BAXTER |
$ | 615 | $ | 535 | $ | 22 | $ | 557 | 10% | |||||||||||
BASIC EPS |
$ | 1.08 | $ | 0.90 | $ | 0.04 | $ | 0.94 | 15% | |||||||||||
DILUTED EPS |
$ | 1.07 | $ | 0.90 | $ | 0.03 | $ | 0.93 | 15% | |||||||||||
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING |
||||||||||||||||||||
Basic |
570 | 593 | 593 | |||||||||||||||||
Diluted |
575 | 596 | 596 | |||||||||||||||||
1 | There were no specified items included in the 2011 GAAP results. | |
2 | Marketing and administrative expenses in 2010 included a charge of $28 million ($22 million, or $0.03 per diluted share, on an after-tax basis) to write down accounts receivable in Greece, principally as a result of the anticipated settlement of certain accounts receivable with the Greek government. | |
3 | Represents the percentage change between the 2011 GAAP results and the 2010 results excluding the specified item. |
For more information on the companys use of non-GAAP financial measures in this press release,
please see the companys Current Report on Form 8-K filed with the Securities and Exchange
Commission on the date of this press release.
BAXTER PAGE 9
BAXTER INTERNATIONAL INC.
Consolidated Statements of Income
Six Months Ended June 30, 2011 and 2010
(unaudited)
(in millions, except per share and percentage data)
Consolidated Statements of Income
Six Months Ended June 30, 2011 and 2010
(unaudited)
(in millions, except per share and percentage data)
Six Months Ended | ||||||||||||
June 30, | ||||||||||||
2011 | 2010 | Change | ||||||||||
NET SALES |
$ | 6,820 | $ | 6,121 | A | 11% | ||||||
COST OF SALES |
3,310 | 3,440 | A | (4% | ) | |||||||
GROSS MARGIN |
3,510 | 2,681 | 31% | |||||||||
% of Net Sales |
51.5% | 43.8% | 7.7 pts | |||||||||
MARKETING AND ADMINISTRATIVE EXPENSES |
1,481 | 1,404 | B | 5% | ||||||||
% of Net Sales |
21.7% | 22.9% | (1.2 pts | ) | ||||||||
RESEARCH AND DEVELOPMENT EXPENSES |
453 | 446 | 2% | |||||||||
% of Net Sales |
6.6% | 7.3% | (0.7 pts | ) | ||||||||
NET INTEREST EXPENSE |
25 | 44 | (43% | ) | ||||||||
OTHER EXPENSE, NET |
17 | 5 | N/M | |||||||||
PRE-TAX INCOME |
1,534 | 782 | 96% | |||||||||
INCOME TAX EXPENSE |
328 | 305 | C | 8% | ||||||||
% of Pre-Tax Income |
21.4% | 39.0% | (17.6 pts | ) | ||||||||
NET INCOME |
1,206 | 477 | 153% | |||||||||
LESS: NONCONTROLLING INTERESTS |
21 | 5 | N/M | |||||||||
NET INCOME ATTRIBUTABLE TO BAXTER |
$ | 1,185 | $ | 472 | 151% | |||||||
BASIC EPS |
$ | 2.07 | $ | 0.79 | 162% | |||||||
DILUTED EPS |
$ | 2.05 | $ | 0.78 | 163% | |||||||
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING |
||||||||||||
Basic |
573 | 597 | ||||||||||
Diluted |
578 | 602 | ||||||||||
ADJUSTED PRE-TAX INCOME (excluding specified items) |
$ | 1,534 | $ | 1,398 | D | 10% | ||||||
ADJUSTED NET INCOME ATTRIBUTABLE TO BAXTER (excluding specified items) |
$ | 1,185 | $ | 1,121 | D | 6% | ||||||
ADJUSTED DILUTED EPS (excluding specified items) |
$ | 2.05 | $ | 1.86 | D | 10% |
A | Net sales and cost of sales in the first quarter of 2010 included a charge totaling $588 million, or $0.98 per diluted share, which related to the recall of COLLEAGUE infusion pumps from the U.S. market and other actions the company is undertaking outside of the United States, for which there was no net tax benefit recognized. | |
B | Marketing and administrative expenses in the second quarter of 2010 included a charge of $28 million ($22 million, or $0.03 per diluted share, on an after-tax basis) to write down accounts receivable in Greece, principally as a result of the anticipated settlement of certain accounts receivable with the Greek government. | |
C | Income tax expense in the first quarter of 2010 included a charge of $39 million, or $0.07 per diluted share, to write off a deferred tax asset as a result of a change in the tax treatment of reimbursements under the Medicare Part D retiree prescription drug subsidy program. | |
D | Refer to page 10 for a description of the adjustments and a reconciliation to GAAP measures. |
BAXTER PAGE 10
BAXTER INTERNATIONAL INC.
Note to Consolidated Statements of Income
Six Months Ended June 30, 2011 and 2010
Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures
(unaudited)
(in millions, except per share and percentage data)
Note to Consolidated Statements of Income
Six Months Ended June 30, 2011 and 2010
Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures
(unaudited)
(in millions, except per share and percentage data)
The companys GAAP results for the six months ended June 30, 2010 included specified items
which impacted the GAAP results as follows:
Six Months Ended June 30, | ||||||||||||||||||||
2011 | 2010 | |||||||||||||||||||
Total | Excluding | |||||||||||||||||||
specified | specified | |||||||||||||||||||
GAAP | 1 | GAAP | items | 2 | items | Change | 3 | |||||||||||||
NET SALES |
$ | 6,820 | $ | 6,121 | $ | 213 | $ | 6,334 | 8% | |||||||||||
COST OF SALES |
3,310 | 3,440 | (375 | ) | 3,065 | 8% | ||||||||||||||
GROSS MARGIN |
3,510 | 2,681 | 588 | 3,269 | 7% | |||||||||||||||
% of Net Sales |
51.5% | 43.8% | 51.6% | (0.1 pt) | ||||||||||||||||
MARKETING AND ADMINISTRATIVE EXPENSES |
1,481 | 1,404 | (28 | ) | 1,376 | 8% | ||||||||||||||
% of Net Sales |
21.7% | 22.9% | 21.7% | 0 pts | ||||||||||||||||
RESEARCH AND DEVELOPMENT EXPENSES |
453 | 446 | | 446 | 2% | |||||||||||||||
% of Net Sales |
6.6% | 7.3% | 7.0% | (0.4 pts) | ||||||||||||||||
NET INTEREST EXPENSE |
25 | 44 | | 44 | (43% | ) | ||||||||||||||
OTHER EXPENSE, NET |
17 | 5 | | 5 | N/M | |||||||||||||||
PRE-TAX INCOME |
1,534 | 782 | 616 | 1,398 | 10% | |||||||||||||||
INCOME TAX EXPENSE |
328 | 305 | (33 | ) | 272 | 21% | ||||||||||||||
% of Pre-Tax Income |
21.4% | 39.0% | 19.5% | 1.9 pts | ||||||||||||||||
NET INCOME |
1,206 | 477 | 649 | 1,126 | 7% | |||||||||||||||
LESS: NONCONTROLLING INTERESTS |
21 | 5 | | 5 | N/M | |||||||||||||||
NET INCOME ATTRIBUTABLE TO BAXTER |
$ | 1,185 | $ | 472 | $ | 649 | $ | 1,121 | 6% | |||||||||||
BASIC EPS |
$ | 2.07 | $ | 0.79 | $ | 1.09 | $ | 1.88 | 10% | |||||||||||
DILUTED EPS |
$ | 2.05 | $ | 0.78 | $ | 1.08 | $ | 1.86 | 10% | |||||||||||
WEIGHTED-AVERAGE NUMBER OF COMMON
SHARES
OUTSTANDING |
||||||||||||||||||||
Basic |
573 | 597 | 597 | |||||||||||||||||
Diluted |
578 | 602 | 602 | |||||||||||||||||
1 | There were no specified items included in the 2011 GAAP results. | |
2 | Net sales and cost of sales in the first quarter of 2010 included a charge totaling $588 million, or $0.98 per diluted share, which related to the recall of COLLEAGUE infusion pumps from the U.S. market and other actions the company is undertaking outside of the United States, for which there was no net tax benefit recognized. Marketing and administrative expenses in the second quarter of 2010 included a charge of $28 million ($22 million, or $0.03 per diluted share, on an after-tax basis) to write down accounts receivable in Greece, principally as a result of the anticipated settlement of certain accounts receivable with the Greek government. Income tax expense in the first quarter of 2010 included a charge of $39 million, or $0.07 per diluted share, to write off a deferred tax asset as a result of a change in the tax treatment of reimbursements under the Medicare Part D retiree prescription drug subsidy program. | |
3 | Represents the percentage change between the 2011 GAAP results and the 2010 results excluding specified items. |
For more information on the companys use of non-GAAP financial measures in this press release,
please see the companys Current Report on Form 8-K filed with the Securities and Exchange
Commission on the date of this press release.
BAXTER PAGE 11
BAXTER INTERNATIONAL INC.
Cash Flows from Operations and Changes in Net Debt
(unaudited)
($ in millions)
Cash Flows from Operations and Changes in Net Debt
(unaudited)
($ in millions)
Cash Flows from Operations | ||||||||||||||||
(Brackets denote cash outflows) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Net income |
$ | 629 | $ | 537 | $ | 1,206 | $ | 477 | ||||||||
Adjustments |
||||||||||||||||
Depreciation and amortization |
169 | 169 | 327 | 335 | ||||||||||||
Deferred income taxes |
69 | 29 | 160 | 120 | A | |||||||||||
Stock compensation |
33 | 33 | 61 | 63 | ||||||||||||
Realized excess tax benefits from stock issued
under employee benefit plans |
(8 | ) | (3 | ) | (13 | ) | (34 | ) | ||||||||
COLLEAGUE infusion pump charge |
| | | 588 | ||||||||||||
Greece receivable charge |
| 28 | | 28 | ||||||||||||
Other |
10 | (4 | ) | 18 | 5 | |||||||||||
Changes in balance sheet items |
||||||||||||||||
Accounts and other current receivables |
(89 | ) | (5 | ) | (157 | ) | (38 | ) | ||||||||
Inventories |
(153 | ) | (25 | ) | (214 | ) | (119 | ) | ||||||||
Accounts payable and accrued liabilities |
11 | (51 | ) | (124 | ) | (152 | ) | |||||||||
Infusion pump and business optimization
payments |
(87 | ) | (18 | ) | (147 | ) | (41 | ) | ||||||||
Other |
48 | 93 | (114 | ) B | (170 | ) B | ||||||||||
Cash flows from operations |
$ | 632 | $ | 783 | $ | 1,003 | $ | 1,062 | ||||||||
Changes in Net Debt
|
||||||||||||||||
Increase (decrease)
|
||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Net debt, beginning of period |
$ | 2,206 | $ | 2,080 | $ | 1,702 | $ | 1,365 | ||||||||
Cash flows from operations |
(632 | ) | (783 | ) | (1,003 | ) | (1,062 | ) | ||||||||
Capital expenditures |
210 | 237 | 408 | 467 | ||||||||||||
Dividends |
178 | 174 | 358 | 348 | ||||||||||||
Proceeds from stock issued under employee benefit plans |
(162 | ) | (61 | ) | (291 | ) | (201 | ) | ||||||||
Purchases of treasury stock |
478 | 677 | 1,115 | 1,112 | ||||||||||||
Acquisitions and investments |
188 | C | 20 | 202 | C | 254 | C | |||||||||
Divestiture and other |
(106 | ) | | (106 | ) | | ||||||||||
Other, including the effect of exchange rate changes |
22 | 170 | (3 | ) | 231 | |||||||||||
Increase in net debt |
176 | 434 | 680 | 1,149 | ||||||||||||
Net debt, June 30 |
$ | 2,382 | $ | 2,514 | $ | 2,382 | $ | 2,514 | ||||||||
Key statistics, June 30: |
||||||||||||||||
Days sales outstanding |
57.8 | 54.3 | 57.8 | 54.3 | ||||||||||||
Inventory turns |
2.5 | 2.5 | 2.5 | 2.5 | ||||||||||||
Selected balance sheet information: | June 30, 2011 | December 31, 2010 | ||||||
Cash and equivalents |
$2,018 | $2,685 | ||||||
Accounts and other current
receivables |
$2,491 | $2,265 | ||||||
Inventories |
$2,648 | $2,371 | ||||||
Accounts payable and accrued liabilities |
$4,009 | $4,017 |
A | Deferred income taxes in the first quarter of 2010 included a charge of $39 million to write off a deferred tax asset as a result of a change in the tax treatment of reimbursements under the Medicare Part D retiree prescription drug subsidy program. | |
B | Other cash flows from operations included planned contributions to the companys pension plan in the United States of $150 million and $300 million in the first quarters of 2011 and 2010, respectively. | |
C | Acquisitions and investments in 2011 and 2010 principally related to the second quarter 2011 acquisition of Prism Pharmaceuticals, Inc., a specialty pharmaceutical company based in the United States, and the first quarter 2010 acquisition of ApaTech Limited, an orthobiologic products company based in the United Kingdom. |
BAXTER PAGE 12
BAXTER INTERNATIONAL INC.
Net Sales
Periods Ending June 30, 2011 and 2010
(unaudited)
($ in millions)
Net Sales
Periods Ending June 30, 2011 and 2010
(unaudited)
($ in millions)
Q2 | Q2 | % Growth @ | % Growth @ | YTD | YTD | % Growth @ | % Growth @ | |||||||||||||||||||||||||||||
2011 | 2010 | Actual Rates | Constant Rates | 2011 | 2010 | Actual Rates | Constant Rates | |||||||||||||||||||||||||||||
BioScience |
||||||||||||||||||||||||||||||||||||
United States |
$ | 687 | $ | 636 | 8% | 8% | $ | 1,371 | $ | 1,246 | 10% | 10% | ||||||||||||||||||||||||
International |
866 | 722 | 20% | 11% | 1,590 | 1,474 | 8% | 5% | ||||||||||||||||||||||||||||
Total BioScience |
$ | 1,553 | $ | 1,358 | 14% | 10% | $ | 2,961 | $ | 2,720 | 9% | 7% | ||||||||||||||||||||||||
Medical Products 1 |
||||||||||||||||||||||||||||||||||||
United States 2 |
$ | 722 | $ | 710 | 2% | 2% | $ | 1,452 | $ | 1,384 | 5% | 5% | ||||||||||||||||||||||||
International |
1,251 | 1,114 | 12% | 4% | 2,389 | 2,206 | 8% | 4% | ||||||||||||||||||||||||||||
Total Medical Products Adjusted 2 |
$ | 1,973 | $ | 1,824 | 8% | 3% | $ | 3,841 | $ | 3,590 | 7% | 4% | ||||||||||||||||||||||||
COLLEAGUE infusion pump charge
2 |
(213 | ) | ||||||||||||||||||||||||||||||||||
Total Medical Products GAAP 2 |
$ | 1,973 | $ | 1,824 | 8% | 3% | $ | 3,841 | $ | 3,377 | 14% | 11% | ||||||||||||||||||||||||
Transfusion Therapies 3 |
||||||||||||||||||||||||||||||||||||
United States |
$ | 9 | $ | 9 | 0% | 0% | $ | 17 | $ | 18 | (6% | ) | (6% | ) | ||||||||||||||||||||||
International |
1 | 3 | (67% | ) | (67% | ) | 1 | 6 | (83% | ) | (83% | ) | ||||||||||||||||||||||||
Total Transfusion Therapies |
$ | 10 | $ | 12 | (17% | ) | (17% | ) | $ | 18 | $ | 24 | (25% | ) | (25% | ) | ||||||||||||||||||||
Baxter International Inc. |
||||||||||||||||||||||||||||||||||||
United States 2 |
$ | 1,418 | $ | 1,355 | 5% | 5% | $ | 2,840 | $ | 2,648 | 7% | 7% | ||||||||||||||||||||||||
International |
2,118 | 1,839 | 15% | 7% | 3,980 | 3,686 | 8% | 4% | ||||||||||||||||||||||||||||
Total Baxter - Adjusted
2 |
$ | 3,536 | $ | 3,194 | 11% | 6% | $ | 6,820 | $ | 6,334 | 8% | 5% | ||||||||||||||||||||||||
COLLEAGUE infusion
pump charge
2 |
(213 | ) | ||||||||||||||||||||||||||||||||||
Total Baxter - GAAP 2 |
$ | 3,536 | $ | 3,194 | 11% | 6% | $ | 6,820 | $ | 6,121 | 11% | 9% | ||||||||||||||||||||||||
1 | Medical Products represents the combination of the companys former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation. | |
2 | GAAP net sales in the first quarter of 2010 included a charge of $213 million related to the recall of COLLEAGUE infusion pumps. Refer to page 16 for a reconciliation to GAAP measures. | |
3 | Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the Transfusion Therapies (TT) business after the February 2007 divestiture. |
BAXTER PAGE 13
BAXTER INTERNATIONAL INC.
GAAP Key Product Line Sales
Periods Ending June 30, 2011 and 2010
(unaudited)
($ in millions)
GAAP Key Product Line Sales
Periods Ending June 30, 2011 and 2010
(unaudited)
($ in millions)
GAAP | GAAP | % Growth @ | % Growth @ | GAAP | GAAP | % Growth @ | % Growth @ | |||||||||||||||||||||||||||||
Q2 2011 | Q2 2010 | Actual Rates | Constant Rates | YTD 2011 | YTD 2010 | Actual Rates | Constant Rates | |||||||||||||||||||||||||||||
BioScience |
||||||||||||||||||||||||||||||||||||
Recombinants |
$ | 570 | $ | 525 | 9% | 3% | $ | 1,082 | $ | 1,035 | 5% | 2% | ||||||||||||||||||||||||
Plasma Proteins |
363 | 314 | 16% | 11% | 671 | 606 | 11% | 9% | ||||||||||||||||||||||||||||
Antibody Therapy |
381 | 310 | 23% | 21% | 755 | 632 | 19% | 19% | ||||||||||||||||||||||||||||
Regenerative Medicine |
147 | 133 | 11% | 6% | 287 | 252 | 14% | 12% | ||||||||||||||||||||||||||||
Other 1 |
92 | 76 | 21% | 12% | 166 | 195 | (15% | ) | (19% | ) | ||||||||||||||||||||||||||
Total BioScience |
$ | 1,553 | $ | 1,358 | 14% | 10% | $ | 2,961 | $ | 2,720 | 9% | 7% | ||||||||||||||||||||||||
Medical Products 2 |
||||||||||||||||||||||||||||||||||||
Renal |
$ | 633 | $ | 585 | 8% | 2% | $ | 1,220 | $ | 1,169 | 4% | 0% | ||||||||||||||||||||||||
Global Injectables |
506 | 472 | 7% | 3% | 1,023 | 923 | 11% | 9% | ||||||||||||||||||||||||||||
IV Therapies |
452 | 418 | 8% | 3% | 880 | 809 | 9% | 6% | ||||||||||||||||||||||||||||
Infusion Systems 3 |
233 | 216 | 8% | 5% | 444 | 212 | 110% | 106% | ||||||||||||||||||||||||||||
Anesthesia |
143 | 130 | 10% | 8% | 261 | 257 | 2% | 0% | ||||||||||||||||||||||||||||
Other |
6 | 3 | 100% | 25% | 13 | 7 | 86% | 20% | ||||||||||||||||||||||||||||
Total Medical Products 3 |
$ | 1,973 | $ | 1,824 | 8% | 3% | $ | 3,841 | $ | 3,377 | 14% | 11% | ||||||||||||||||||||||||
Transfusion Therapies4 |
$ | 10 | $ | 12 | (17% | ) | (17% | ) | $ | 18 | $ | 24 | (25% | ) | (25% | ) | ||||||||||||||||||||
Total Baxter 3 |
$ | 3,536 | $ | 3,194 | 11% | 6% | $ | 6,820 | $ | 6,121 | 11% | 9% | ||||||||||||||||||||||||
1 | Principally includes vaccines and sales of plasma to third parties. | |
2 | Medical Products represents the combination of the companys former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation. | |
3 | GAAP net sales in the first quarter of 2010 included a charge of $213 million related to the recall of COLLEAGUE infusion pumps. Refer to page 16 for a reconciliation to GAAP measures. | |
4 | Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture. |
BAXTER PAGE 14
BAXTER INTERNATIONAL INC.
Adjusted Key Product Line Sales
Periods Ending June 30, 2011 and 2010
(unaudited)
($ in millions)
Adjusted Key Product Line Sales
Periods Ending June 30, 2011 and 2010
(unaudited)
($ in millions)
GAAP | GAAP | % Growth @ | % Growth @ | GAAP | Adjusted | % Growth @ | % Growth @ | |||||||||||||||||||||||||||||
Q2 2011 | 1 | Q2 2010 | 1 | Actual Rates | Constant Rates | YTD 2011 | 1 | YTD 2010 | Actual Rates | Constant Rates | ||||||||||||||||||||||||||
BioScience |
||||||||||||||||||||||||||||||||||||
Recombinants |
$ | 570 | $ | 525 | 9% | 3% | $ | 1,082 | $ | 1,035 | 5% | 2% | ||||||||||||||||||||||||
Plasma Proteins |
363 | 314 | 16% | 11% | 671 | 606 | 11% | 9% | ||||||||||||||||||||||||||||
Antibody Therapy |
381 | 310 | 23% | 21% | 755 | 632 | 19% | 19% | ||||||||||||||||||||||||||||
Regenerative Medicine |
147 | 133 | 11% | 6% | 287 | 252 | 14% | 12% | ||||||||||||||||||||||||||||
Other 2 |
92 | 76 | 21% | 12% | 166 | 195 | (15% | ) | (19% | ) | ||||||||||||||||||||||||||
Total BioScience |
$ | 1,553 | $ | 1,358 | 14% | 10% | $ | 2,961 | $ | 2,720 | 9% | 7% | ||||||||||||||||||||||||
Medical Products 3 |
||||||||||||||||||||||||||||||||||||
Renal |
$ | 633 | $ | 585 | 8% | 2% | $ | 1,220 | $ | 1,169 | 4% | 0% | ||||||||||||||||||||||||
Global Injectables |
506 | 472 | 7% | 3% | 1,023 | 923 | 11% | 9% | ||||||||||||||||||||||||||||
IV Therapies |
452 | 418 | 8% | 3% | 880 | 809 | 9% | 6% | ||||||||||||||||||||||||||||
Infusion Systems - Adjusted 4 |
233 | 216 | 8% | 5% | 444 | 425 | 4% | 3% | ||||||||||||||||||||||||||||
Anesthesia |
143 | 130 | 10% | 8% | 261 | 257 | 2% | 0% | ||||||||||||||||||||||||||||
Other |
6 | 3 | 100% | 25% | 13 | 7 | 86% | 20% | ||||||||||||||||||||||||||||
Total Medical Products - Adjusted 4 |
$ | 1,973 | $ | 1,824 | 8% | 3% | $ | 3,841 | $ | 3,590 | 7% | 4% | ||||||||||||||||||||||||
Transfusion Therapies 5 |
$ | 10 | $ | 12 | (17% | ) | (17% | ) | $ | 18 | $ | 24 | (25% | ) | (25% | ) | ||||||||||||||||||||
Total Baxter - Adjusted 4 |
$ | 3,536 | $ | 3,194 | 11% | 6% | $ | 6,820 | $ | 6,334 | 8% | 5% | ||||||||||||||||||||||||
1 | There were no adjustments included in the 2011 GAAP results or the Q2 2010 GAAP results. | |
2 | Principally includes vaccines and sales of plasma to third parties. | |
3 | Medical Products represents the combination of the companys former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation. | |
4 | Adjusted net sales in the first quarter of 2010 excluded a charge of $213 million related to the recall of COLLEAGUE infusion pumps. Refer to page 16 for a reconciliation to GAAP measures. | |
5 | Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture. |
BAXTER PAGE 15
BAXTER INTERNATIONAL INC.
Key Product Line Sales by U.S. and International
Three-Month Periods Ending June 30, 2011 and 2010
(unaudited)
($ in millions)
Key Product Line Sales by U.S. and International
Three-Month Periods Ending June 30, 2011 and 2010
(unaudited)
($ in millions)
Q2 2011 | Q2 2010 | % Growth | |||||||||||||||||||||||||||||||||||||||
U.S. | International | Total | U.S. | International | Total | U.S. | International | Total | |||||||||||||||||||||||||||||||||
BioScience |
|||||||||||||||||||||||||||||||||||||||||
Recombinants |
$ | 239 | $ | 331 | $ | 570 | $ | 233 | $ | 292 | $ | 525 | 3% | 13% | 9% | ||||||||||||||||||||||||||
Plasma Proteins |
103 | 260 | 363 | 110 | 204 | 314 | (6% | ) | 27% | 16% | |||||||||||||||||||||||||||||||
Antibody Therapy |
261 | 120 | 381 | 211 | 99 | 310 | 24% | 21% | 23% | ||||||||||||||||||||||||||||||||
Regenerative Medicine |
78 | 69 | 147 | 76 | 57 | 133 | 3% | 21% | 11% | ||||||||||||||||||||||||||||||||
Other 1 |
6 | 86 | 92 | 6 | 70 | 76 | 0% | 23% | 21% | ||||||||||||||||||||||||||||||||
Total BioScience |
$ | 687 | $ | 866 | $ | 1,553 | $ | 636 | $ | 722 | $ | 1,358 | 8% | 20% | 14% | ||||||||||||||||||||||||||
Medical Products 2 |
|||||||||||||||||||||||||||||||||||||||||
Renal |
$ | 97 | $ | 536 | $ | 633 | $ | 98 | $ | 487 | $ | 585 | (1% | ) | 10% | 8% | |||||||||||||||||||||||||
Global Injectables |
255 | 251 | 506 | 263 | 209 | 472 | (3% | ) | 20% | 7% | |||||||||||||||||||||||||||||||
IV Therapies |
144 | 308 | 452 | 134 | 284 | 418 | 7% | 8% | 8% | ||||||||||||||||||||||||||||||||
Infusion Systems |
137 | 96 | 233 | 132 | 84 | 216 | 4% | 14% | 8% | ||||||||||||||||||||||||||||||||
Anesthesia |
88 | 55 | 143 | 84 | 46 | 130 | 5% | 20% | 10% | ||||||||||||||||||||||||||||||||
Other |
1 | 5 | 6 | (1 | ) | 4 | 3 | N/M | 25% | 100% | |||||||||||||||||||||||||||||||
Total Medical Products |
$ | 722 | $ | 1,251 | $ | 1,973 | $ | 710 | $ | 1,114 | $ | 1,824 | 2% | 12% | 8% | ||||||||||||||||||||||||||
Transfusion Therapies3 |
$ | 9 | $ | 1 | $ | 10 | $ | 9 | $ | 3 | $ | 12 | 0% | (67% | ) | (17% | ) | ||||||||||||||||||||||||
Total Baxter |
$ | 1,418 | $ | 2,118 | $ | 3,536 | $ | 1,355 | $ | 1,839 | $ | 3,194 | 5% | 15% | 11% | ||||||||||||||||||||||||||
1 | Principally includes vaccines and sales of plasma to third parties. | |
2 | Medical Products represents the combination of the companys former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation. | |
3 | Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture. |
BAXTER PAGE 16
BAXTER INTERNATIONAL INC.
Reconciliation of GAAP to Non-GAAP Net Sales Measures
Periods Ending June 30, 2011 and 2010
(unaudited)
($ in millions)
Reconciliation of GAAP to Non-GAAP Net Sales Measures
Periods Ending June 30, 2011 and 2010
(unaudited)
($ in millions)
The companys GAAP net sales results for the six months ended June 30, 2010 included a $213
million charge related to the recall of COLLEAGUE infusion pumps, which impacted GAAP net sales as
follows:
% Growth @ | % Growth @ | |||||||||||||||||||||||||||||||||||||||||||||||||||||
2011 YTD | 2010 YTD | Actual Rates | Constant Rates | |||||||||||||||||||||||||||||||||||||||||||||||||||
U.S. | International | Total | U.S. | International | Total | U.S. | International | Total | U.S. | International | Total | |||||||||||||||||||||||||||||||||||||||||||
Infusion Systems - GAAP |
$ | 444 | $ | 212 | 110% | 106% | ||||||||||||||||||||||||||||||||||||||||||||||||
COLLEAGUE infusion
pump charge |
213 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Infusion Systems - Adjusted |
$ | 444 | $ | 425 | 4% | 3% | ||||||||||||||||||||||||||||||||||||||||||||||||
Total Medical Products - GAAP |
$ | 1,452 | $ | 2,389 | $ | 3,841 | $ | 1,171 | $ | 2,206 | $ | 3,377 | 24% | 8% | 14% | 24% | 4% | 11% | ||||||||||||||||||||||||||||||||||||
COLLEAGUE infusion
pump charge |
213 | 213 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Total Medical Products - Adjusted |
$ | 1,452 | $ | 2,389 | $ | 3,841 | $ | 1,384 | $ | 2,206 | $ | 3,590 | 5% | 8% | 7% | 5% | 4% | 4% | ||||||||||||||||||||||||||||||||||||
Total Baxter - GAAP |
$ | 2,840 | $ | 3,980 | $ | 6,820 | $ | 2,435 | $ | 3,686 | $ | 6,121 | 17% | 8% | 11% | 17% | 4% | 9% | ||||||||||||||||||||||||||||||||||||
COLLEAGUE infusion
pump charge |
213 | 213 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Total Baxter - Adjusted |
$ | 2,840 | $ | 3,980 | $ | 6,820 | $ | 2,648 | $ | 3,686 | $ | 6,334 | 7% | 8% | 8% | 7% | 4% | 5% | ||||||||||||||||||||||||||||||||||||
For more information on the companys use of non-GAAP financial measures in this press release,
please see the companys Current Report on Form 8-K filed with the Securities and Exchange
Commission on the date of this press release.